SCHEMBL4869703

SCHEMBL4869703

CCN(CCCNC(=O)N1CCCOc2ccccc21)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.58
GLA P06280 1/20 0.58
MAPT P10636 6/20 0.50
ALDH1A1 P00352 5/20 0.50
MEN1 O00255 3/20 0.50
LMNA P02545 3/20 0.50
GAA P10253 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
TSHR P16473 1/20 0.50
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
RXFP1 Q9HBX9 1/20 0.45
THRB P10828 1/20 0.45
OPRK1 P41145 1/20 0.45
HSD17B10 Q99714 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4871913 0.92 KMT2A (0.50) KMT2AGLAMAPTALDH1A1MEN1
SCHEMBL4869531 0.89 KMT2A (0.47) KMT2AGLAMAPTALDH1A1MEN1
SCHEMBL4860776 0.83 LMNA (0.43) KMT2AGLAMAPTALDH1A1MEN1
SCHEMBL4863777 0.82 KMT2A (0.55) KMT2AGLAMAPTMEN1LMNA
SCHEMBL4868271 0.79 KMT2A (0.52) KMT2AGLAMAPTMEN1LMNA
SCHEMBL4865179 0.75 GFER (0.53) KMT2AMAPTMEN1LMNACYP1A2
SCHEMBL4869509 0.74 AVPR2 (0.52) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL4871095 0.73 MAPT (0.43) KMT2AMAPTALDH1A1MEN1LMNA
SCHEMBL4870682 0.73 AVPR2 (0.51) KMT2AMAPTALDH1A1MEN1LMNA
SCHEMBL4866999 0.73 MAPT (0.61) KMT2AMAPTMEN1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 KMT2A 2577/4885GLA 3116/4885MAPT 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.